A Phase I study of Anetumab Ravtansine in Combination with either Anti-PD-1 Antibody, or Anti-CTLA4 and Anti-PD-1 Antibodies or Anti-PD-1 Antibody and Gemcitabine in Mesothelin-Positive Advanced Pancreatic Adenocarcinoma
This Study is
No Longer Enrolling
Details
Age
Adult
Eligibility
patients must have mesothelin-positive advanced pancreatic cancer
Phase
I - Research Studies that focus on the safety of a drug. The goal is to determine the drug's most frequent and serious adverse events and, often, how the drug is broken down and excreted by the body. These studies usually involve a small number of participants.
Type of Study
Treatment
Locations
University of Colorado Hospital
Study ID
Protocol Number: 19-0821
More information available at ClinicalTrials.gov: NCT03816358
Categories
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers